ReviewGlobal health & medicine2023
COVID-19 vaccination program in Cambodia: Achievements and remaining challenges.
Review in Global health & medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Measles vaccination perceptions and willingness to consider novel vaccination approaches in Cambodia's floating villages.Journal of virology · 2026Article
- Understanding the drivers and barriers of elderly vaccination in post-pandemic China: a qualitative study in Shenzhen.BMC public health · 2025Article
- Estimating the Global, Regional, and National Economic Costs of COVID-19 Vaccination During the COVID-19 Pandemic.Vaccines · 2025Article
- Global disparities in the introduction, scale-up, and effectiveness evaluation of COVID-19 vaccines.Nature communications · 2025Article
- Reaching the unreached through building trust: a mixed-method study on COVID-19 vaccination in rural Lao PDR.BMJ global health · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since Cambodia has been recognized as one of the low- and middle-income countries with a successful COVID-19 vaccine program, its program approaches were reviewed based mainly on press articles and announcements from the Ministry of Health. From the beginning, the government's proactive approach to securing vaccines and its flexibility prior to WHO Emergency Use Listing (EUL) contributed greatly to the success of the program. Vaccines were provided by COVAX and other countries, but more than half of the vaccines secured were Chinese vaccines purchased with government funds. The rollout of the vaccine has also been flexible, moving from a strategy of prioritizing risk groups and essential workers to one of expanding the campaign from population centers to rural areas, as well as gradually expanding the target age group, eventually targeting the population age 3 and older. As a result of this high level of commitment by the government and its flexible response, Cambodia has achieved 95% primary series coverage of the entire population, including those not eligible for vaccination. Although the sixth booster is now being administered in Cambodia and vaccination every six months was recommended, several challenges might be anticipated in continuing this program, including the lack of clear global guidance on how to sustain and modify the COVID-19 immunization program and vaccine fatigue after COVID-19 outbreaks have been controlled. How these challenges are overcome and how the COVID-19 vaccine program remains need to be carefully observed into the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.